
Pipeline
The Future of Drug Discovery
At Cullgen, we believe that the key to advancing medicine lies in redefining the way we approach drug discovery. Our pipeline harnesses the power of state-of-the-art technologies, immense expertise, and an unwavering dedication to developing transformative therapeutics. It is designed to expedite the journey from target identification to clinical candidates, streamlining the drug discovery process and bringing novel treatments to patients faster than ever before. Committed to collaboration and open innovation, our pipeline also offers strategic partnerships with leading biopharmaceutical companies. These alliances foster synergistic advancements in drug discovery, fostering valuable collaborations that enable us to achieve remarkable breakthroughs together.
At Cullgen, our discovery pipeline is poised to revolutionize the field of drug development. By embracing innovation, leveraging cutting-edge technologies, and fostering collaborative partnerships, we are truly transforming the future of medicine, one breakthrough at a time.
Cullgen Novel E3 Ligand Discovery Pipeline
Broad expression & functional essential
E3A
Broad expression & functional essential
E3B
Tissue Restrictive Expression
E3E
E3G
Tumor Enriched Expression
Functional Validation
E3 Selection
E3 Binders Discovery
Lead Optimization
Target
Cullgen Therapeutic Programs: Focused on Cancer
Indication
Target Selection
Lead Optimization
Breast cancer and multiple solid tumors
Hit Discovery
Prostate, lung, and bladder cancers
Breast and ovarian cancers
Cell Cycle (a)
Immuno-oncology of multiple cancer types
Cell Cycle (b)
DNA repair
Metabolism
PCC Selection
IND Enabling
Partnered with Astellas
Clinical trial initiated
Non-enzyme target
Utilizing Cullgen E3 ligands
Phase I
Colon, ovarian, and GI cancers
Solid Tumors
TRK
TRK
Translation
Transcrip-tion
Epigenetic
Acute and chronic pain
Leukemia and MYC+ Cancers
Lymphoma
Descriptions of the projects that are furthest advanced:
Cullgen Novel E3 Ligand Discovery Pipeline
Explanation about this pipeline
Cullgen Therapeutic Programs: Focused on Cancer
Explanation about this pipeline